Risk factors associated with blood transfusion in liver transplantation

Sci Rep. 2024 Aug 16;14(1):19022. doi: 10.1038/s41598-024-70078-2.

Abstract

To explore preoperative and operative risk factors for red blood cell (RBC) transfusion requirements during liver transplantation (LT) and up to 24 h afterwards. We evaluated the associations between risk factors and units of RBC transfused in 176 LT patients using a log-binomial regression model. Relative risk was adjusted for age, sex, and the model for end-stage liver disease score (MELD) (adjustment 1) and baseline hemoglobin concentration (adjustment 2). Forty-six patients (26.14%) did not receive transfusion. Grafts from cardiac-death donors were used in 32.61% and 31.54% of non-transfused and transfused patients, respectively. The transfused group required more reoperation for bleeding (P = 0.035), longer mechanical ventilation after LT (P < 0.001), and longer ICU length of stay (P < 0.001). MELD and hemoglobin concentrations determined RBC requirements. For each unit of increase in the MELD score, 2% more RBC units were transfused, and non-transfusion was 0.83-fold less likely. For each 10-g/L higher hemoglobin concentration at baseline, 16% less RBC transfused, and non-transfusion was 1.95-fold more likely. Ascites was associated with 26% more RBC transfusions. With an increase of 2 mm from the baseline in the A10FIBTEM measurement of maximum clot firmness, non-transfusion was 1.14-fold more likely. A 10-min longer cold ischemia time was associated with 1% more RBC units transfused, and the presence of post-reperfusion syndrome with 45% more RBC units. We conclude that preoperative correction of anemia should be included in LT. An intervention to prevent severe hypotension and fibrinolysis during graft reperfusion should be explored.Trial register: European Clinical Trials Database (EudraCT 2018-002,510-13) and ClinicalTrials.gov (NCT01539057).

Keywords: Blood component transfusion; Hemostasis; Liver transplantation; Mean hemoglobin concentration; Morbidity; Mortality; Thromboelastometry.

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Aged
  • Blood Transfusion
  • End Stage Liver Disease / surgery
  • Erythrocyte Transfusion
  • Female
  • Hemoglobins / analysis
  • Hemoglobins / metabolism
  • Humans
  • Length of Stay
  • Liver Transplantation* / adverse effects
  • Liver Transplantation* / methods
  • Male
  • Middle Aged
  • Risk Factors

Substances

  • Hemoglobins

Associated data

  • ClinicalTrials.gov/NCT01539057

Grants and funding